MONOCLONAL ANTIBODIES AGAINST AMYLOID BETA PROTEIN AND USES THEREOF

• Main Authors: HILLEN HEINZ, LABKOVSKY BORIS, STRIEBINGER ANDREAS R, EBERT ULRICH, STEFAN BARGHORN, KELLER PATRICK
• Format: Patent
• Language: English; Japanese
• Published: 14.04.2016
• Subjects: BEER; BIOCHEMISTRY; CHEMISTRY; COMPOSITIONS THEREOF; CULTURE MEDIA; ENZYMOLOGY; HUMAN NECESSITIES; HYGIENE; INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIRCHEMICAL OR PHYSICAL PROPERTIES; MEASURING; MEDICAL OR VETERINARY SCIENCE; METALLURGY; MICROBIOLOGY; MICROORGANISMS OR ENZYMES; MUTATION OR GENETIC ENGINEERING; ORGANIC CHEMISTRY; PEPTIDES; PHYSICS; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS; SPIRITS; TESTING; VINEGAR; WINE

PROBLEM TO BE SOLVED: To provide monoclonal antibodies usable for prevention, treatment and diagnosis of Alzheimer's Disease and other neurodegenerative diseases.SOLUTION: The invention relates to a monoclonal antibody comprising a variable heavy chain and a variable light chain where the three complementarity determining region (CDR) of respective variable heavy chain and variable light chain have specified amino acid sequences, and the monoclonal antibody binds to an amyloid beta protein globulomer with higher specificity than to an amyloid beta protein monomer. The monoclonal antibody is produced by a hybridoma having American Type Culture Collection Designation Number PTA-7238. Also provided is a method for diagnosing Alzheimer's disease in a subject by contacting the antibody with a biological sample isolated from a patient suspected of having Alzheimer's Disease.SELECTED DRAWING: Figure 1 【課題】アルツハイマー病又はその他の神経変性疾患の、予防、治療及び診断において使用され得るモノクローナル抗体の提供。【解決手段】可変重鎖及び可変軽鎖を含むモノクローナル抗体であって、該可変重鎖及び該可変軽鎖の各々の３つの相補性決定領域（ＣＤＲ）は特定のアミノ酸配列を有し、アミロイドベータタンパク質単量体に対してよりもアミロイドベータタンパク質球状凝集体に対して高い特異性で結合するモノクローナル抗体。前記モノクローナル抗体は、Ａｍｅｒｉｃａｎ Ｔｙｐｅ Ｃｕｌｔｕｒｅ Ｃｏｌｌｅｃｔｉｏｎ指定番号ＰＴＡ−７２３８を有するハイブリドーマにより産生される。アルツハイマー病を有する疑いのある患者から単離した生体試料と前記抗体を接触し、該患者におけるアルツハイマー病の診断をする方法。【選択図】図１